3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
18
Ovarian Neoplasms
8
Neoplasms
7
Colorectal Neoplasms
5
Recurrence
4
Small Cell Lung Carcinoma
3
Prostatic Neoplasms
3
Glioblastoma
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Radiation Pneumonitis
2
Peritoneal Neoplasms
2
Mesothelioma, Malignant
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Fallopian Tube Neoplasms
2
Carcinoma, Renal Cell
2
Thyroid Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Solid Tumors
1
Sarcoma
1
Rectal Neoplasms
1
Patients With Any Advanced Solid Tumors
1
Pancreatic Neoplasms
1
Ovarian Diseases
1
Oligodendroglioma
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasm Metastasis
1
Interventions
Sirolimus
9
Everolimus
5
Imatinib Mesylate
2
temsirolimus
1
saracatinib
1
nintedanib
1
carbon-11 acetate
1
Valproic Acid
1
Sugars
1
Simvastatin
1
Resveratrol
1
Octreotide
1
Loratadine
1
Letrozole
1
Immunoglobulin G
1
Hydroxychloroquine
1
Glutamine
1
Doxycycline
1
Disulfides
1
Cetuximab
1
Celecoxib
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Lymphangioleiomyomatosis
×
nintedanib
×
Clear all
NCT03062943
2022-09-28
LAM
IRCCS Multimedica
Phase 2
Completed
30 enrolled